Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Wockhardt's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Wockhardt's Dividend Payout Ratio or its related term are showing as below:
NSE:WOCKPHARMA's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.38 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Wockhardt was -12.60% per year. The lowest was -20.60% per year. And the median was -16.60% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Wockhardt (NSE:WOCKPHARMA) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Wockhardt Dividend Payout Ratio Related Terms
Wockhardt Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Wockhardt's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WOCKPHARMA vs ZTS: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Wockhardt's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Wockhardt's Dividend Payout Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (NSE:WOCKPHARMA) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Wockhardt and its competitors. According to the industry distribution chart, Wockhardt ranks #999999 out of 444 companies in the Drug Manufacturers industry.
Is Wockhardt's Dividend Payout Ratio too high?
Wockhardt's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Wockhardt ranks #999999 out of 444 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wockhardt has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Dividend Payout Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #999999 out of 444 companies for Dividend Payout Ratio. This places Wockhardt in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 444 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,246.45, compared to a current price of ₹1,865.20 — trading 49.6% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Wockhardt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,865.20 is trading 49.6% above its estimated GF Value™ of ₹1,246.45.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
Dividend Payout Ratio: 0.00
GF Value™: ₹1,246.45 vs. price of ₹1,865.20 (49.6% above fair value)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
61GF Score
Get the complete analysis for NSE:WOCKPHARMA
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
